BioLife Solutions sets up shop in Indianapolis, adding a slate of new cell and gene therapy tools to its belt
How far can $24 million get you? For Washington-based BioLife Solutions, the answer is all the way to Indianapolis.
BioLife Solutions, a top provider of tools and services for cell and gene therapy development, is putting down a modest $24 million to snap up all the shares in Sexton Biotechnologies it doesn’t already own, the partners said on Monday. In the process, it’s getting a slate of new bioproduction tools, and the deed to Sexton’s downtown Indianapolis facility.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.